Ask Warren

Hwail Pharm

061250 · KOSDAQ · ₩061250 · 화일약품

₩5,750▼ ₩70 (1.20%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −49.69%
Market cap
₩48B
Enterprise value
−₩42B
P/E
11.6×
P/B
0.2×
Dividend yield
0.0%
ROE
2.0%
Net margin
4.6%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−54.0% from the high

₩5,660Today: ₩5,740 – ₩5,830₩12,500

Returns

  • 1W−4.0%
  • 1M−9.4%
  • 3M−34.9%
  • 6M−39.0%
  • YTD−49.7%
  • 1Y−49.7%
Volume today
4,562
0.4× the 20-day average
Traded today
₩26M
Listed shares
8,417,584
EPS (12 months)
₩495
Earnings yield 8.6%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

31Quiet
  • BuzzQuietBuzz 31 of 100 (50 is a normal day for this stock).
  • MomentumWeak-10.4% over the last month; the price is below its 20-day average.

Signals describe activity, not recommendations. Not financial advice.

Hwail Pharm stock overview

Hwail Pharm (화일약품, KRX: 061250) is listed on KOSDAQ, in the Biotech & Pharma sector. The company manufactures and sells active and inactive pharmaceutical ingredients for drug production, along with cephalosporin antibiotic finished drugs and functional health food raw materials. Its shares closed at ₩5,750 on Oct 27, 2026, down 1.20% on the day, giving it a market value of ₩48B.

Key facts

Market cap
₩48B
Sector
Biotech & Pharma
Latest price change
−1.20%
As of
Oct 27, 2026
Main business
The company manufactures and sells active and inactive pharmaceutical ingredients for drug production, along with cephalosporin antibiotic finished drugs and functional health food raw materials.

Quick answers about Hwail Pharm

What does Hwail Pharm do?
The company manufactures and sells active and inactive pharmaceutical ingredients for drug production, along with cephalosporin antibiotic finished drugs and functional health food raw materials. It operates from a headquarters in Pangyo and three domestic production plants in Gyeonggi-do, including Hwaseong and Ansan, and sells mainly in South Korea, where about 99% of its 2024 sales were generated.
What is the market cap of Hwail Pharm?
The market capitalisation of Hwail Pharm was ₩48B at the close on Oct 27, 2026.
Who are the largest shareholders of Hwail Pharm?
According to the latest official filings, the largest reported holders are Osung Advanced Materials (42.10%, as of Sep 18, 2026); Pharma & Bio New Technology Investment Partnership (27.84%, as of Sep 18, 2026); Geumho HT (10.92%, as of Apr 16, 2026).
When is the next earnings report from Hwail Pharm?
Korean companies rarely announce results dates in advance. Based on when Hwail Pharm filed the same report in past years, its next 3q results is expected between Nov 13, 2026 and Nov 14, 2026.

Company profile

The company manufactures and sells active and inactive pharmaceutical ingredients for drug production, along with cephalosporin antibiotic finished drugs and functional health food raw materials. It operates from a headquarters in Pangyo and three domestic production plants in Gyeonggi-do, including Hwaseong and Ansan, and sells mainly in South Korea, where about 99% of its 2024 sales were generated.

Written by AI from the company's latest annual report.

Korean name
화일약품
Sector
Biotech & Pharma
Themes
Pharmaceuticals
CEO
김유정, 서생규 (각자 대표이사)
Founded
Nov 1980
Listed
Apr 2002
Listed shares
8,417,584
Fiscal year ends
Month 12
Website
www.hwail.com

Similar companies

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Hwail Pharm / 화일약품 / 061250 / KRX:061250

Source: KRX statistical information